Intravenous Immunoglobulin (IVIG) Market Analysis 2022-2030- Increase In Prevalence Of Immunodeficiency Diseases And Rise In Adoption Of Immunoglobulin Therapies Are Key Factors Driving Market Revenue Growth

Rising incidence of immunodeficiency diseases and increase in geriatric population are key factors driving market revenue growth.

Rising incidence of immunodeficiency diseases and increase in geriatric population are key factors driving market revenue growth

Global Intravenous Immunoglobulin (IVIG) market size is expected to reach USD 20.22 Billion in 2030 and register revenue CAGR of 6.9% over the forecast period, according to latest report by Reports and Data. Rising incidence of immunodeficiency diseases and steady increase in geriatric population are key factors expected to drive market revenue growth over the forecast period.

With rise in cases of primary and acquired immunodeficiency diseases and disorders such as hypogammaglobulinemia, immunodeficiency diseases, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre syndrome, Kawasaki disease, healthcare ecosystem gets affected by rising demand to allocate resources in a more diversified manner to fulfil needs of changing healthcare dynamics. Healthcare infrastructure faces more burden with steadily growing pool of patients with immunoglobulin deficiency. With increase in awareness and adoption of IVIG therapies, demand for getting proper treatment rises which creates a strong demand for plasma market. Hence with changing healthcare dynamics, need for proper allocation of resources is of high importance for healthcare management. Proper allocation of resources boosts the entire supply chain and accounts for growth of IVIG market.

Access Free sample PDF Copy of the Report @ https://www.reportsanddata.com/sample-enquiry-form/1442

Immunoglobulin helps to treat these immunodeficiency diseases and disorders efficiently and effectively. This drags medical experts for novel immunoglobulin therapies, safe to administer with minimal side effects. In cases of primary immunodeficiency that affects antibody production, immunoglobulin replacement therapies are considered one of the most successful. According to the American College of Rheumatology, intravenous immunoglobulin provides significant-good results and is used for treatments such as Kawasaki disease, a rheumatologic disease in children. IVIG is also used for treating patients with inflammatory muscle diseases, including dermatomyositis, polymyositis, and juvenile dermatomyositis. IVIG is considered first line of treatment for adult Immune Thrombocytopenia (ITP) and is more effective than other conventional therapies. In systematic lupus erythematosus, IVIG is also used as a therapy to boost abnormally low platelet count, or red blood cells count. Thus, with increase in immunodeficiency diseases, neurological and bleeding disorders, high efficacy of IVIG has a significant positive impact on market growth.

However, high cost of IVIG therapies is the primary factor that is expected to hamper market revenue growth. In addition, stringent regulatory policies by various governments will restrain market revenue growth.

Some Key Highlights in the Report

  • Hypogammaglobulinemia segment is expected to lead in terms of revenue contribution to global market. Hypogammaglobulinemia is the most prevalent primary immunodeficiency and encompasses a majority of immune-compromised patients caused by low antibody levels. Standard treatment for hypogammaglobulinemia is IgG replacement to minimize potentially fatal infection and reduce complications, thus improving patients’ survival and quality of life.
  • Liquid segment is expected to account for larger market share over the forecast period. Liquid form is more convenient to patients owing to relatively shorter time of infusion process. In addition, ease of preparation and administration for health workers and patients makes it most acceptable which augment growth for this segment.
  • North America will account for the largest market share in IVIG market over the forecast period due to increasing number of patients with immunology disorders and rising geriatric population
  • Companies in global market report include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd, Shanghai RAAS Blood Products Co., Ltd, CSL Behring LLC, ADMA Biologics, Inc., Baxalta Inc., Biotest AG, Kedrion Biopharma, Inc., China Biologic Products Holdings, Inc., Octapharma AG, Grifols S.A., Pfizer Inc., and LFB Biomedicaments SA.
  • In August 2021, ADMA Biologics, Inc. received Food and Drug Administration (FDA) approval for Maryville’s ADMA Biocenters plasma collection facility. Introduction of new plasma collection facility helps to secure raw material plasma supply and helps the company to ensure itself from border market plasma collection and pricing fluctuations.

Get In detailed Research Study @ https://www.reportsanddata.com/report-detail/intravenous-immunoglobulin-market

For this report, Reports and Data has segmented Intravenous Immunoglobulin (IVIG) market based on product type, application, form, end-use, and region.

Product Type Outlook (Revenue, USD Billion; (2019-2030)

  • Immunoglobulin G (IgG)
  • Immunoglobulin A (IgA)
  • Immunoglobulin M (IgM)
  • Immunoglobulin E (IgE)
  • Immunoglobulin D (IgD)

Application Outlook (Revenue, USD Billion; 2019-2030)

  • Hypogammaglobulinemia
  • Immunodeficiency Diseases
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Congenital AIDS
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Guillain-Barre syndrome
  • Kawasaki Diseases
  • Others

Form Outlook (Revenue, USD Billion; 2019-2030)

  • Liquid
  • Lyophilized

End-Use Outlook (Revenue, USD Billion; 2019-2030)

  • Hospitals
  • Clinics
  • Homecare
  • Others

Regional Outlook (Revenue, USD Billion; 2019-2030)

  • Middle East & Africa
  • Asia Pacific
  • Europe
  • North America
  • Saudi Africa

Ask for Customize Research Report @ https://www.reportsanddata.com/request-customization-form/1442

Some points on how the report benefits stakeholders:

  • The reports include historical (2019–2020) and forecast (2021–2030) data points, revenues, and CAGR in table, figure, and chart formats, with detailed and qualitative, supporting written information for each.
  • Revenue break-up is provided for each segment in these formats for global, regional, and for each country in the respective region for each year between 2019 and 2030.
  • The report contains insights regarding growth drivers, restraints, opportunities, trends, company profiles, strategic developments, expansion details, product launches, and various other aspects related to the market.
  • The report contains data and information on customers, competitors, vendors/distributors, and other players and in the global marketplace.
  • Market research analysis is vital for all crucial business strategies and can aid in numerous ways and to provide a clearer understanding about strategies being deployed by competitors, product launches, competitive analysis, technological advancements and various other factors that enhance sales of a firm or perhaps provide insights to focus on merger and acquisition as a strategy or enter into strategic agreements or joint ventures etc.
  • The report contains company profiles of the top companies operating in the market along with their respective revenue and operating segments, geographical reach, market footprint, headquarters, growth rates, recent developments, product /services, expansion strategies, investments in expansion, and more.

Explore Latest Trending Research Reports By Reports and Data’s

Rare Dermatological Disease Treatment Market By Diseases (Epidermolysis Bullosa, Hailey Hailey Disease, Systemic Sclerosis, Interstitial Granulomatous Dermatitis (IGD), Pemphigus, Acral Peeling Skin Syndrome, Argyria, Morgellons, Keratosis Follicularis, Erythropoietic Protoporphyria (EPP), Elastoderma, Others), By Treatment (Corticosteroids, Immunosuppressants, Anti-inflammatory Agents, Antibiotics, Analgesics, Others), By Distribution, and By Region Forecast to 2028

Cholera Vaccines Market By Type (Dukoral, Shanchol, Vaxchora, Euvichol & Euvichol-plus, Others), By Application (Hospitals & Clinics, Research & Academic Laboratories, Pharmaceutical & Biotechnology Companies, Others), and By Region Forecast 2028

Snake Anti-Venom Market Size, Share And Industry Analysis By Product Type (Polyvalent, Monovalent, and Others), By Species (Snake and Others), By End-Use (Hospitals, Clinics and Ambulatory Hospitals), and By Region Forecast to 2028

Electrocardiogram Equipment Market Size, Share And Industry Analysis By Type (Resting ECG System, Holter Monitors, Stress ECG Monitors, and Event Monitors), By Application (Hospitals, Ambulatory Care, and Others), and By 0Region Forecast To 2028

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Read Latest Press Release @ https://www.reportsanddata.com/press-release/global-intravenous-immunoglobulin-ivig-market